Protagonist Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Dinesh V. Patel
- Full Time Employees
- 124
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 7707 Gateway Boulevard Newark CA United States of America 94560-1160
- IPO Date
- Aug 11, 2016
- CIK
- 0001377121
- Website
- protagonist-inc.com
- Similar Companies
- Business
- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) is a clinical-stage biopharmaceutical company that develops novel peptide-based therapeutics targeting unmet needs in hematology, blood disorders, inflammatory, and immunomodulatory diseases. The company leverages a proprietary peptide technology platform, including molecular design tools such as Vectrix™, phage display libraries, oral stability assays, and advanced peptide chemistry, to engineer potent, selective peptides with oral bioavailability for targets like cytokines, receptors, transporters, GPCRs, and ion channels. Its lead product candidates include rusfertide (PTG-300), a hepcidin mimetic in Phase 3 (VERIFY trial) and Phase 2 extensions (REVIVE, THRIVE) for polycythemia vera; and the oral IL-23R antagonist JNJ-2113 (formerly PN-235 or PTG-200), partnered with Janssen (Johnson & Johnson), in Phase 3 for plaque psoriasis and Phase 2b (ANTHEM) for ulcerative colitis; alongside early-stage discovery programs like PN-477 (multi-receptor agonist for obesity), PN-881 (psoriasis), and others for hemochromatosis and hematologic diseases. Founded in 2006 and headquartered in Newark, California, Protagonist operates primarily in the United States with additional presence in Australia. Recent developments include positive Phase 3 data for icotrokinra (JNJ-2113) in plaque psoriasis driving a 32% stock surge in October 2025, plans for a New Drug Application submission for rusfertide in late 2025, advancement of early pipeline candidates with Phase 1 initiations targeted for Q4 2025, and ongoing acquisition discussions with Johnson & Johnson, which already holds a 4% equity stake and commercialization rights to certain assets.
Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026
J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?
Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration
Protagonist Therapeutics Reports Granting of Inducement Awards
SG Americas Securities LLC Sells 21,249 Shares of Protagonist Therapeutics, Inc. $PTGX
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Protagonist Partners With Johnson & Johnson To Compete With AbbVie's Skyrizi
Protagonist Therapeutics Soars as FDA Approves ICOTYDE for Plaque Psoriasis, Triggers $50M Milestone
Protagonist Therapeutics Stock Rallies Nearly 7% in a Week: Here's Why
Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock?
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of ICOTYDE for Moderate to Severe Plaque Psoriasis Treatment Transcript
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
Protagonist Therapeutics, Inc. (PTGX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
Citigroup Inc. Has $10.14 Million Stake in Protagonist Therapeutics, Inc. $PTGX
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update